Landscapes / Targets
MET
43 drugs act on MET, in 117 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs43
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Tyrosine kinase inhibitor |
CSPC · Public 1093.HK |
Approved in China | 25 Dec 2026Phase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 25 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | C-Met Exon 14 Mutation, Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression and 3 more | ||||
| Open drug page | |||||
MET inhibitor |
HUTCHMED +1 · Public AZN |
Approved in China | 18 Jan 2027Phase 2 trial completes | ||
| Next date | 18 Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Carcinoma, Non-Small Cell Lung Cancer and 11 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Novartis · Public NVS |
Approved | 30 Jul 2027Phase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 30 Jul 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumors Which Are cMET-dependent, EGFR-mutant Non-small Cell Lung Cancer | ||||
| Open drug page | |||||
C-Met-targeted antibody-drug conjugate |
AbbVie · Public ABBV |
Approved | Feb 2028Phase 2 trial completes | ||
| Next date | Feb 2028 · Phase 2 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, c-MET and 2 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Pfizer · Public PFE |
Approved | 21 Mar 2028Phase 4 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 21 Mar 2028 · Phase 4 trial completes | ||||
| Also tested for | Carcinoma, Non-Small-Cell Lung, NSCLC and 2 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | — | |||
| How it works | Blocks a kinase | ||||
| Also tested for | Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | 15 Dec 2026soonPhase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 15 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Colorectal Cancer, Renal Cell Carcinoma and 32 more | ||||
| Open drug page | |||||
Monoclonal antibody |
AbbVie · Public ABBV |
Phase 3 | Dec 2026Phase 2 trial completes | ||
| How it works | An antibody | ||||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Colorectal Cancer, Non-Small Cell Lung Cancer and 27 more | ||||
| Open drug page | |||||
— |
Phase 3 | Jan 2027Phase 3 trial completes | |||
| Next date | Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Thyroid Cancer | ||||
| Open drug page | |||||
— |
Phase 2/3 | 30 Apr 2027Phase 1 trial completes | |||
| Next date | 30 Apr 2027 · Phase 1 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Colorectal Cancer and 5 more | ||||
| Open drug page | |||||
MET inhibitor unconfirmed |
Phase 3 | 31 Oct 2027Phase 3 trial completes | |||
| Next date | 31 Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Locally Advanced or Metastatic NSCLC and 3 more | ||||
| Open drug page | |||||
— |
Lantern Pharma +1 |
Phase 2 | Dec 2026Phase 2 trial completes | ||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Renal Cell Carcinoma, Differentiated Thyroid Carcinoma and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Feb 2027Phase 1/2 trial completes | |||
| Next date | Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Malignant Tumors, Esophageal Cancer and 1 more | ||||
| Open drug page | |||||
— |
Kelun-Biotech · Public 6990.HK |
Phase 2 | 30 Jun 2027Phase 2 trial completes | ||
| Next date | 30 Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Solid Malignancies, Lung Cancer (Non-Small Cell) and 5 more | ||||
| Open drug page | |||||
— |
Regeneron · Public REGN |
Phase 1/2 | 6 Jul 2027Phase 1/2 trial completes | ||
| Next date | 6 Jul 2027 · Phase 1/2 trial completes | ||||
| Also tested for | NSCLC | ||||
| Open drug page | |||||
— |
Phase 1/2 | 31 Aug 2027Phase 1/2 trial completes | |||
| Next date | 31 Aug 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Cancer, RAS/BRAF Wild Type Colorectal Cancer and 3 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 12 Nov 2027Phase 1/2 trial completes | |||
| Next date | 12 Nov 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Dec 2027Phase 2 trial completes | |||
| Next date | 30 Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Metastatic Colorectal Cancer, Unresectable/Metastatic Colorectal Cancer | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Apr 2028Phase 1/2 trial completes | |||
| Next date | 30 Apr 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Solid Tumor and 4 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 43 of 43 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026